FDA-approved
Sexual & reproductive
Degarelix
Evidence
FDA approved
Class
GnRH antagonist
KEY TAKEAWAY
Degarelix is a ten-amino-acid GnRH antagonist. It is sold as Firmagon. The FDA approved degarelix (Firmagon) in 2008 for advanced prostate cancer.
Written by the Veylo editorial team · Updated
November 2026
What it is
GnRH antagonist
Approved for
Advanced prostate cancer
Key fact
The FDA approved degarelix (Firmagon) in 2008 for advanced prostate cancer.
Route
Monthly subcutaneous injection
Evidence strength
FDA approved
Degarelix is a ten-amino-acid GnRH antagonist. It is sold as Firmagon.
It blocks GnRH receptors, which quickly lowers testosterone without the early surge seen with GnRH agonists.
The FDA approved degarelix (Firmagon) in 2008 for advanced prostate cancer.
Advanced prostate cancer.
Hot flashes, injection-site reactions, weight gain and liver enzyme increases are common. Long-term testosterone lowering affects bone and heart health.
U.S. FDA prescribing information for Degarelix. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.